首页 | 本学科首页   官方微博 | 高级检索  
     


11C‐PE2I and 18F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study
Authors:Andreas A. Roussakis MD  Antonio Martín‐Bastida MD  MSc  Natalie Valle‐Guzman MSc  Gesine Paul MD  PhD  Clare Loane PhD  Håkan Widner MD  PhD  Marios Politis MD  PhD   MRCP  Tom Foltynie MD  PhD   FRCP  Roger A. Barker PhD  MBBS   MRCP  Paola Piccini MD  PhD   FRCP
Affiliation:1. Centre for Neurodegeneration and Neuroinflammation, Division of Brain Sciences, Imperial College London, London, UK;2. John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK;3. Translational Neurology Group, Department of Clinical Sciences, Wallenberg Neuroscience Centre, Lund University, Lund, Sweden;4. Division of Neurology, Department of Clinical Sciences, Lund University, Sk?ne University Hospital, Lund, Sweden;5. Memory Research Group, Nuffield Department of Clinical Neurosciences, Medical Science Division. University of Oxford, Oxford, UK;6. Neurodegeneration Imaging Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK;7. Sobell Department of Motor Neuroscience, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
Abstract:
Keywords:Parkinson's disease  dopamine transporter  aromatic l‐amino acid decarboxylase  11C‐PE2I  18F‐dopa
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号